Compositions and method for treating primary sclerosing cholangitis and related disorders

11213,549

16/340215

October 11, 2017

The present disclosure is in the field of pharmaceutical compositions suitable for the treatment of diseases in mammals. The disclosure provides novel compositions comprising non-pathogenic fecal microbes for treating primary sclerosing cholangitis and related diseases. The disclosure also provides methods for treating a subject with the compositions disclosed herein.

Finch Therapeutics Holdings LLC (Somerville, MA, US)

Finch Therapeutics Holdings LLC (Somerville, MA, US)

1. A method for treating primary sclerosing cholangitis (PSC) in a human subject in need thereof, the method comprising orally administering to the human subject a pharmaceutically active therapeutic composition comprising a non-selected fecal microbiota derived from a stool of a healthy human donor, wherein the human subject is pretreated with an antibiotic, and wherein a level of serum alkaline phosphatase (SAP) in the subject is reduced by at least 4-fold compared to a level of SAP in the human subject prior to the antibiotic pretreatment.

2. The method of claim 1 , wherein the composition is administered at least once per day for at least two days in a week.

3. The method of claim 1 , wherein the composition is administered at least once per day for at least five days in a week.

4. The method of claim 1 , wherein the composition is administered at least once per day for at least two consecutive days.

5. The method of claim 1 , wherein the composition is administered at least once per day for at least five consecutive days.

6. The method of claim 1 , wherein the PSC is selected from the group consisting of: stage 1, stage 2, stage 3, and stage 4 PSC.

7. The method of claim 1 , wherein the composition comprises a cryoprotectant.

8. The method of claim 7 , wherein the cryoprotectant is selected from the group consisting of polyethylene glycol, skim milk, erythritol, arabitol, sorbitol, glucose, fructose, alanine, glycine, proline, sucrose, lactose, ribose, trehalose, dimethyl sulfoxide (DMSO), glycerol, and a combination thereof.

9. The method of claim 8 , wherein the cryoprotectant is trehalose.

10. The method of claim 1 , wherein the composition is in a liquid, frozen, freeze-dried, spray-dried, foam-dried, or powder form.

11. The method of claim 1 , wherein the composition is formulated as a delayed or gradual enteric release form.

12. The method of claim 1 , wherein the composition is formulated as an enteric-coated capsule or an acid-resistant capsule.

13. The method of claim 1 , wherein the method eliminates or reduces one or more symptoms selected from the group consisting of: fatigue, itchiness, jaundice, inflammation of the bile ducts, fever, upper abdominal pain, impairment of bile secretion, easy bruising, greasy and foul-smelling stools, gallstones, bile duct stones, anemia, osteoporosis, cirrhosis of the liver, portal hypertension, ascites, liver failure, and cholangiocarcinoma.

14. The method of claim 1 , wherein the method reduces the level of disease indicators selected from the group consisting of: serum bilirubin, serum aminotransferase, alkaline phosphatase, gamma-glutamyltransferase (GGT), gamma globulin, IgM, serum alkaline phosphatase, and a combination thereof after at least 8 weeks of treatment.

15. The method of claim 1 , wherein the composition is administered at least once daily for at least two weeks.

16. The method of claim 1 , wherein the composition is administered at least twice weekly for at least two weeks.

17. The method of claim 1 , wherein the composition is administered at least twice weekly for at least four weeks.

18. The method of claim 1 , wherein the composition is administered at least twice weekly for at least eight weeks.

19. The method of claim 1 , wherein the antibiotic is selected from the group consisting of rifabutin, clarithromycin, clofazimine, vancomycin, metronidazole, rifampicin, nitroimidazole, chloramphenicol, rifaximin, a rifamycin derivative, rifapentine, rifalazil, bicozamycin, aminoglycoside, gentamycin, neomycin, streptomycin, paromomycin, verdamicin, mutamicin, sisomicin, netilmicin, retymicin, kanamycin, aztreonam, aztreonam macrolide, dirithromycin, roxithromycin, telithromycin, azithromycin, bismuth subsalicylate, fidaxomicin, amikacin, arbekacin, rhodostreptomycin, tobramycin, apramycin, and a combination thereof.

20. The method of claim 19 , wherein the antibiotic is a combination of vancomycin and metronidazole.

3192116 June 1965 Möse et al.
3320130 May 1967 Henry
3713836 January 1973 Carlsson
4098728 July 1978 Rosenblatt
4309782 January 1982 Paulin
4332790 June 1982 Sozzi et al.
4335107 June 1982 Snoeyenbos et al.
4452779 June 1984 Cockerill
4536409 August 1985 Farrell et al.
4657762 April 1987 Mikkola et al.
4710379 December 1987 Kawai et al.
4892731 January 1990 Arai et al.
4975286 December 1990 Hechter
5213807 May 1993 Chemburkar et al.
5266315 November 1993 Taguchi et al.
5443826 August 1995 Borody
5728380 March 1998 Allen et al.
5800821 September 1998 Acheson et al.
5837238 November 1998 Casas et al.
5858356 January 1999 Wolf et al.
5902578 May 1999 Halpin-Dohnalek et al.
5902743 May 1999 Luchansky et al.
6087386 July 2000 Chen et al.
6162464 December 2000 Jacob et al.
6245740 June 2001 Goldenberg et al.
6284274 September 2001 Merrill et al.
6428783 August 2002 Khachatrian et al.
6479051 November 2002 Bruce
6514531 February 2003 Alaux et al.
6645530 November 2003 Borody
6649397 November 2003 Nakamura
6756032 June 2004 Tepper et al.
6926907 August 2005 Plachetka
6979674 December 2005 Goldenberg et al.
6984513 January 2006 Brown et al.
7018629 March 2006 Jacob et al.
7374753 May 2008 Farmer et al.
7541091 June 2009 Sisson et al.
7749509 July 2010 Cobb et al.
7763276 July 2010 Shodai et al.
7799341 September 2010 Porzio et al.
7815956 October 2010 Lee et al.
7846475 December 2010 Shiraishi et al.
7888062 February 2011 Garner et al.
7998510 August 2011 Caswell
8168171 May 2012 Mogna et al.
8460648 June 2013 Borody
8586029 November 2013 Kasper et al.
8637297 January 2014 Fernandez et al.
8658153 February 2014 Daube et al.
8771673 July 2014 Cobb et al.
9040036 May 2015 Borody
9050358 June 2015 Borody
9308226 April 2016 Borody
9320763 April 2016 Borody
9408872 August 2016 Borody
9468658 October 2016 Borody
9572841 February 2017 Borody
9572842 February 2017 Borody
9610308 April 2017 Borody
9623056 April 2017 Borody
9719144 August 2017 Krajmalnik-Brown et al.
2001/0014322 August 2001 Chen et al.
2002/0013270 January 2002 Bolte
2002/0022019 February 2002 Laulund
2002/0039599 April 2002 Lin et al.
2003/0092163 May 2003 Collins et al.
2003/0092724 May 2003 Kao et al.
2003/0147858 August 2003 Renaud et al.
2004/0062757 April 2004 Finegold
2004/0167062 August 2004 Bolte
2004/0170617 September 2004 Finegold
2004/0223956 November 2004 Naidu et al.
2006/0076536 April 2006 Barshied
2006/0099197 May 2006 Farmer
2006/0115465 June 2006 Macfarlane et al.
2006/0177424 August 2006 Cobb et al.
2006/0275223 December 2006 Burr
2007/0059296 March 2007 Chen
2008/0254009 October 2008 Finegold
2008/0299197 December 2008 Toneguzzo et al.
2010/0112003 May 2010 Collins et al.
2010/0178349 July 2010 Kolter et al.
2010/0178413 July 2010 Gorris
2010/0184785 July 2010 Kolter et al.
2010/0222311 September 2010 Thommes et al.
2010/0226866 September 2010 Yamashiro et al.
2010/0233278 September 2010 Ookawa et al.
2010/0239667 September 2010 Hemmingsen et al.
2010/0247489 September 2010 Saur-Brosch et al.
2010/0247665 September 2010 Takahashi
2010/0255231 October 2010 Chau et al.
2010/0255307 October 2010 Gonze et al.
2010/0278930 November 2010 Okumura et al.
2010/0285164 November 2010 Schaible et al.
2010/0289164 November 2010 Porzio et al.
2010/0297031 November 2010 Ubeda Perez et al.
2011/0008554 January 2011 Chen et al.
2011/0045222 February 2011 Peters
2011/0081320 April 2011 Westall et al.
2011/0200570 August 2011 Mosbaugh et al.
2011/0218216 September 2011 Vivek et al.
2012/0020941 January 2012 Wacklin et al.
2012/0039853 February 2012 Corveleyn et al.
2012/0006413 March 2012 Chauhan et al.
2012/0087895 April 2012 Mazmanian et al.
2012/0183612 July 2012 Brogmann et al.
2012/0252775 October 2012 Finegold
2013/0045274 February 2013 Hlavka
2013/0195804 August 2013 Borody
2013/0259899 October 2013 Allen-Vercoe et al.
2013/0316394 November 2013 Stimpson
2014/0065132 March 2014 Hsiao et al.
2014/0086877 March 2014 Hlavka
2014/0147417 May 2014 Sadowsky et al.
2014/0147425 May 2014 Henn et al.
2014/0234260 August 2014 Borody
2014/0255351 September 2014 Berstad et al.
2014/0328803 November 2014 McKenzie et al.
2014/0341921 November 2014 Honda et al.
2014/0342438 November 2014 Allen-Vercoe et al.
2014/0363397 December 2014 Allen-Vercoe et al.
2014/0363398 December 2014 Jones et al.
2014/0363399 December 2014 Jones
2015/0044173 February 2015 Jones et al.
2015/0050246 February 2015 Jones et al.
2015/0093360 April 2015 McKenzie et al.
2015/0143557 May 2015 Honda et al.
2015/0152484 June 2015 Krajmalnik-Brown et al.
2015/0190435 July 2015 Henn et al.
2015/0224152 August 2015 Littman et al.
2015/0238544 August 2015 Jones et al.
2015/0238545 August 2015 Borody
2015/0238546 August 2015 Borody
2015/0297642 October 2015 Borody
2015/0306144 October 2015 Borody
2015/0306155 October 2015 Borody
2015/0306156 October 2015 Borody
2015/0374761 December 2015 Sadowsky et al.
2016/0089363 March 2016 Borody
2016/0151429 June 2016 Borody
2016/0151431 June 2016 Borody
2016/0151432 June 2016 Borody
2016/0151433 June 2016 Borody
2016/0158294 June 2016 Von Maltzahn et al.
2016/0279178 September 2016 Borody
2016/0279179 September 2016 Borody
2016/0339065 November 2016 Adams et al.
2017/0216378 August 2017 Honda et al.
2017/0246220 August 2017 Sato et al.
2017/0348360 December 2017 Borody
2018/0153943 June 2018 Borody
2018/0256652 September 2018 Borody
2019/0015460 January 2019 Borody
2019/0015461 January 2019 Borody
2019/0015462 January 2019 Borody
2019/0046589 February 2019 Borody
2001276160 June 2007
1333564 December 1994
2 391 422 January 2004
1561387 January 2005
101496819 August 2009
201441672 April 2010
2 134 179 January 1973
0 303 426 February 1989
0 456 418 November 1991
0 433 299 May 1998
1 514 572 March 2005
1 514 572 November 2006
1 800 688 June 2007
1 514 572 December 2008
EP2 823 822 October 2016
1275 May 1962
2427 March 1964
2828 October 1964
5528 November 1967
2 244 464 April 1975
1 271 674 April 1972
64-67192 March 1989
H05-306221 November 1993
H07-242539 September 1995
H07-242557 September 1995
3 144 556 March 2001
2004-501095 January 2004
2005-118544 May 2005
2008-106066 May 2008
2010-513359 April 2010
2010-520234 June 2010
10-0913405 August 2009
WO 90/01335 February 1990
WO 95/33046 December 1995
WO 96/11014 April 1996
WO 98/13068 April 1998
WO 00/07571 February 2000
WO 00/015760 March 2000
WO 00/42168 July 2000
WO 02/07741 January 2002
WO 03/033681 April 2003
WO 2005/017095 February 2005
WO 2006/127355 November 2006
WO 2008/077614 July 2008
WO 2008/105715 September 2008
WO 2008/117266 October 2008
WO 2008/117267 October 2008
WO 2008/077614 January 2009
WO 2009/024429 February 2009
WO 2009/026306 February 2009
WO 2009/055362 April 2009
WO 2010/040020 April 2010
WO 2011/033310 March 2011
WO 2011/094027 August 2011
WO 2011/110347 September 2011
WO 2011/151941 December 2011
WO 2012/013861 February 2012
WO 2012/016287 February 2012
WO 2012/045150 April 2012
WO 2012/122478 September 2012
WO 2012/016287 November 2012
WO 2013/037067 March 2013
WO 2013/090825 June 2013
WO 2014/070014 May 2014
WO 2014/078911 May 2014
WO 2014/152338 September 2014
WO 2014/152484 September 2014
WO 2015/006355 January 2015
WO 2015/051323 April 2015
WO 2015/077794 May 2015
WO 2015/095241 June 2015
WO 2015/124637 August 2015
WO 2016/133450 February 2016
WO 2016/183577 November 2016
WO 2016/191356 December 2016
WO 2017/075098 May 2017
WO 2017/152137 September 2017

Williamson et al., New Therapeutic Strategies for Primary Sclerosing Cholangitis. Seminars in liver disease, (Feb. 2016) vol. 36, No. 1, pp. 5-14. Electronic Publication Date: Feb. 12, 2016 (Year: 2016). cited by examiner
Lin etal, Twelve Week Storage Trial of Microbial Viability in Lyophilized and Frozen Fecal Microbiota Preparations. Gastroenterology, (Apr. 2015) vol. 148, No. 4, Suppl. 1, pp. S962 (Year: 2015). cited by examiner
“Autoimmune Disease List,” American Autoimmune Related Diseases Association, pp. 1-4 (2017) . cited by applicant
“Certain infectious and parasitic diseases (A00-B99),” International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10)-WHO Version, Chapter 1, pp. 1 (2016) . cited by applicant
“Spore-Forming Gram-Positive Bacilli: Bacillus and Clostridium Species,” Jawetz, Melnick, & Adelberg's Medical Microbiology, 26th Edition, Chapter 11, pp. 1-15 (2012). cited by applicant
“ARGF—‘Autologous Rehabilitation of Gastrointestinal Flora,’” Medipex Report for Medilink NW, pp. 1-42, n.d., Web, Feb. 10, 2012 . cited by applicant
“Frequently Asked Questions about Clostridium difficile for Healthcare Providers,” Healthcare-associated Infections (HAIs), Centers for Disease Control and Prevention, pp. 1-6, Nov. 25, 2010, updated Mar. 6, 2012, Web, May 19, 2014 . cited by applicant
“Functional Anatomy of Prokaryotic and Eukaryotic Cells,” printed Mar. 16, 2017 . cited by applicant
“Monilia,” Def. 1, Stedman's Medical Dictionary, n.d., Web, Nov. 22, 2005. cited by applicant
“Probiotic,” Def. 1, MSN Encarta—Dictionary, Encarta, n.d., Web, Dec. 1, 2005. cited by applicant
Aas et al., “Recurrent Clostridium difficile Colitis: Case Series Involving 18 Patients Treated with Donor Stool Administered via a Nasogastric Tube,” Clinical Infectious Diseases, 36(5):580-585 (2003). cited by applicant
Abrams, “Open-Label, Uncontrolled Trial of Bowel Sterilization and Repopulation with Normal Bowel Flora for Treatment of Inflammatory Bowel Disease,” Current Therapeutic Research, 58(12):1001-1012 (1997). cited by applicant
Acha et al., “Changes of viability and composition of the Escherichia coli flora in faecal samples during long time storage,” Journal of Microbiological Methods, Elsevier, 63(3):229-238 (2005). cited by applicant
Agrawal et al., “‘Global warming’ to Mycobacterium avium subspecies paratuberculosis,” Future Microbiol, 9(7):829-832 (2014). cited by applicant
Agrawal et al., “A Long-Term Follow-Up Study of the Efficacy and Safety of Fecal Microbiota Transplant (FMT) for Recurrent/Severe/Complicated C. difficile Infection (CDI) in the Elderly,” Gastroenterol, 146(5)(Suppl 1):S42-43 (2014). cited by applicant
Aitken et al., “Demonstration of Intracellular Mycobacterium Species in Crohn's Disease Using Novel Technologies,” Poster Presentation—2015 ACG Annual Scientific Meeting, Honolulu, Hawaii, USA (2015). cited by applicant
Akao et al., “A Purgative Action of Barbaloin Is Induced by Eubacterium sp. Strain BAR, a Human Intestinal Anaerobe, Capable of Transforming Barbaloin to Aloe-Emodin Anthrone,” Biol. Pharm., 19(1):136-138 (1996). cited by applicant
Al-Eidan et al., “Clostridium difficile-associated diarrhoea in hospitalised patients,” J. Clin. Pharm. Ther., 25(2):101-109 (2000). cited by applicant
Al-Nassir et al., “Comparison of Clinical and Microbiological Response to Treatment of Clostridium difficile-Associated Disease with Metronidazole and Vancomycin,” Clin Infect Dis., 47(1):56-62 (2008). cited by applicant
Anand et al., “Epidemiology, clinical manifestations, and outcome of Clostridium difficile-associated diarrhea,” Am J Gastroenterol., 89(4):519-23 (1994). cited by applicant
Ananthakrishnan et al., “Excess hospitalisation burden associated with Clostridium difficile inpatients with inflammatory bowel disease,” Gut, 570:205-210 (2007). cited by applicant
Anderson et al., “Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease,” Aliment. Pharmacol. Ther., 36:503-16 (2012). cited by applicant
Andoh et al., “Terminal restriction fragment polymorphisum analyses of fecal microbiota in five siblings including two with ulcerative colitis,” Journal of Clinical Gastroenterology, 2:343-345 (2009). cited by applicant
Andrews et al., “‘Putting back the bugs’: Bacterial Treatment Relieves Chronic Constipation and Symptoms of Irritable Bowel Syndrome,” Med. J. Aust., 159(9):633-634 (1993). cited by applicant
Andrews et al., “Bacteriotherapy for Chronic Constipation—A Long Term Follow-Up,” Gastroenterol, 108:A563 Abstract (1995). cited by applicant
Andrews et al., “Chronic Constipation (CC) may be reversed by Bacteriotherapy,” Gastroenterol, 106:A59 (1994). cited by applicant
Andrews et al., “Chronic constipation reversed by restoration of bowel flora. A case and a hypothesis,” European Journal of Gastroenterology & Hepatology, 4:245-247 (1992). cited by applicant
Anorexia nervosa, Encyclopedia Index A, healthAtoZ, Medical Network, Inc., pp. 1-7, n.d., Web, Nov. 23, 2005 . cited by applicant
Arkkila et al., “Fecal Bacteriotherapy for Recurrent Clostridium difficile Infection,” Gastroenterology, 138(5):S1-S5 (2010). cited by applicant
Aroniadis et al., “Intestinal Microbiota and the Efficacy of Fecal Microbiota Transplantation in Gastrointestinal Disease,” Gastroenterology and Hepatology, 10(4): 230-7 (2014). cited by applicant
Aroniadis et al., “Long-Term Follow-up Study of Fecal Microbiota Transplantation (FMT) for Severe or Complicated Clostridium difficile Infection (CDI),” Gastroenterol, 144(Suppl 1):S185 (2013). cited by applicant
Atarashi et al., “Induction of Colonic Regulatory T Cells by Indigenous Clostridium Species,” Science, 331(6015):337-341, published online Dec. 23, 2010. cited by applicant
Atarashi et al., “Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota,” Nature, 500(7461):232-236 (2013). cited by applicant
Atarashi et al., “WS/PP-064-03 Regulation of colonic regulatory T cells by Clostridium species,” International Immunology, 22(Suppl 1, Part 3), pp. 1-3 (2010). cited by applicant
Atarashi et al., WS-064 Mucosal immunity: homeostasis, 14th ICIC Abstract book, 14th International Congress of Immunology, pp. iii131-iii133 (2010). cited by applicant
Autism, Health Encyclopedia—Diseases and Conditions, The Health Scout Network, pp. 1-5, n.d., Web, Nov. 22, 2005 . cited by applicant
Autism, Treatment, Prognosis, Healthcommunities.com, Inc., pp. 1-4, n.d., Web. Jan. 28, 2009 . cited by applicant
Autism: Mayo Clinic.com, Mayo Foundation for Medical Education and Research, pp. 1-7, May 31, 2008, Web. Jan. 28, 2009 . cited by applicant
Backhed et al., “Host-bacterial mutualism in the human intestine,” Science, 307(5717):1915-1920 (2005). cited by applicant
Backhed et al., “Mechanisms underlying the resistance to diet-induced obesity in germ-free mice,” PNAS USA, 104(3):979-984 (2007). cited by applicant
Backhed et al., “The gut microbiota as an environmental factor that regulates fat storage,” PNAS USA, 101(44):15718-15723 (2004). cited by applicant
Bakken et al., “Fecal bacteriotherapy for recurrent Clostridium difficile infection,” Anaerobe, 15(6):285-289 (2009). cited by applicant
Bakken et al., “Treating Clostridium difficile Infection with Fecal Microbiota Transplantation,” Clinical Gastroenterology and Hepatology, 9(12):1044-1049 (2011). cited by applicant
Bartlett et al., “Clinical recognition and diagnosis of Clostridium difficile infection,” Clin Infect Dis., 46(Suppl 1):S12-S18 (2008). cited by applicant
Bartlett, “Clostridium difficile-associated Enteric Disease,” Curr Infect Dis Rep., 4(6):477-483 (2002). cited by applicant
Belkaid et al., “Natural regulatory T cells in infectious disease,” Nature Immunology, 6(4):353-360 (2005). cited by applicant
Bengmark et al., “Bioecological control of inflammatory bowel disease,” Clinical Nutrition, 26(2):169-181 (2007). cited by applicant
Bennet et al., “Treatment of ulcerative colitis by implantation of normal colonic flora,” Lancet, 333(8630):164 (1989). cited by applicant
Benson et al., “Changing epidemiology of Clostridium difficile-associated disease in children,” Infect Control Hosp Epidemiol., 28(11):1233-1235 (2007). cited by applicant
Bergey's Manual of Systematic Bacteriology, Second Edition, vol. Three, The Firmicutes, pp. 1-16 (2009). cited by applicant
Blaser et al., “What are the consequences of the disappearing human microbiota?” Nat. Rev. Microbiol., 7(12):887-894 (2009). cited by applicant
Blaser, “Who are we? Indigenous microbes and the ecology of human diseases,” EMBO Rep, 7(10):956-960 (2006). cited by applicant
Bolte, “Autism and Clostridium tetani,” Medical Hypotheses, 51(2):133-144 (1998). cited by applicant
Bolte, “Therapies for Gastrointestinal and Neurological Disorders.” U.S. Appl. No. 60/214,813, filed Jun. 28, 2000. cited by applicant
Borody et al., “Fecal microbiota transplantation in gastrointestinal disease: 2015 update and the road ahead,” Expert Review of Gastroenterology and Hepatology, 9(11):1379-1391 (2015). cited by applicant
Borody et al., “Anti-MAP Rescues Anti-TNF Failures for Over 4 Years,” Gastroenterol, 136(5)Suppl 1:A-681 (2009). cited by applicant
Borody et al., “Anti-MAP Therapy for Pediatric Crohn's Disease,” Am J Gastroenterol, 108(Suppl 1):S516 (2013). cited by applicant
Borody et al., “Anti-MAP Therapy in the Treatment of Active Crohn's Disease,” J Gastroenterol & Hepatol, 20(Suppl):A2 (2005). cited by applicant
Borody et al., “Anti-mycobacterial therapy in Crohn's disease heals mucosa with longitudinal scars,” Digestive & Liver Disease, 39(5):438-444 (2007). cited by applicant
Borody et al., “Anti-Mycobacterium avium SS Paratuberculosis (MAP) Therapy and Fistula Closure in Patients with Severe Crohn's Disease,” Am J Gast, A101:S440 (2006). cited by applicant
Borody et al., “Bacteriotherapy in Chronic Fatigue Syndrome (CFS): A retrospective review,” Am J Gastro, 107(S1):A1481 (2012). cited by applicant
Borody et al., “Bacteriotherapy Using Fecal Flora: toying with human motions” J. Clin. Gastroenterol., 38(6):475-483 (2004). cited by applicant
Borody et al., “Bowel-flora alteration: a potential cure for inflammatory bowel disease and irritable bowel syndrome?” Med. J. Aust., 150:604 (1989). cited by applicant
Borody et al., “Changes in Crohn's Disease Activity Index and C-Reactive Protein Levels During Anti-MAP Therapy,” Am J Gastro, 104(S3):A1293 (2009). cited by applicant
Borody et al., “Clostridium difficile Complicating Inflammatory Bowel Disease: Pre- and Post-Treatment Findings,” Gastroenterol, 134(4)Suppl 1:A-361 (2008). cited by applicant
Borody et al., “Could fecal microbiota transplantation cure all Clostridium difficile infections?,” Future Microbiol, 9:1-3 (2014). cited by applicant
Borody et al., “Entamoeba histolytica: another cause of Crohn's Disease,” Am J Gastro, 104(S3):A990 (2009). cited by applicant
Borody et al., “Faecal bacteriotherapy (FB) for chronic C. difficile (Cd) syndromes,” J Gastroenterol Hepatol, 18(Suppl.):B8 (Abstract) (2003). cited by applicant
Borody et al., “Fecal bacteriotherapy in the treatment of recurrent C. difficile infection,” UpToDate, pp. 1-6 (2006). cited by applicant
Borody et al., “Fecal Microbiota Transplantation (FMT) in Multiple Sclerosis (MS),” Am J Gastro, 106(S2):A942 (2011). cited by applicant
Borody et al., “Fecal microbiota transplantation and emerging applications,” Nat. Rev. Gastroenterol. Hepatol., 9(2):88-96 (2011). cited by applicant
Borody et al., “Fecal microbiota transplantation for Clostridium difficile infection: A surgeon's perspective” Seminars in Colon and Rectal Surgery, 25:163-166 (2014). cited by applicant
Borody et al., “Fecal microbiota transplantation in gastrointestinal diseases—What practicing physicians should know,” Polish Archives of Internal Medicine, 125(11):852-858 (2015). cited by applicant
Borody et al., “Fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection,” UpToDate, pp. 1-4, (2015). cited by applicant
Borody et al., “Fecal Microbiota Transplantation in Ulcerative Colitis: Review of 24 Years Experience,” Am J Gastro, 107(Supp 1):A1644 (2012). cited by applicant
Borody et al., “Fecal microbiota transplantation: a new standard treatment option for Clostridium difficile infection,” Expert Rev Anti Infect Ther., 11(5):447-449 (2013). cited by applicant
Borody et al., “Fecal microbiota transplantation: current status and future directions,” Expert Review of Gastroenterology & Hepatology, 5(6):653-655 (2011). cited by applicant
Borody et al., “Fecal Microbiota Transplantation: Expanding Horizons for Clostridium difficile Infections and Beyond,” Antibiotics, 4:254-266 (2015). cited by applicant
Borody et al., “Fecal Microbiota Transplantation: Indications, Methods, Evidence, and Future Directions,” Curr Gastroenterol Rep, 15:337-344 (2013). cited by applicant
Borody et al., “Fecal Microbiota Transplantation: Techniques, Applications, and Issues,” Gastroenterol Clin North Am, 47:781-803 (2012). cited by applicant
Borody et al., “Irritable Bowel Syndrome and Dientamoeba fragilis,” ASM Sydney National Conference, pp. 4-5 (2002). cited by applicant
Borody et al., “Is Crohn's Disease Ready for Fecal Microbiota Transplantation?,” J Clin Gastroenterol, 48(7):582-583 (2014). cited by applicant
Borody et al., “Myoclonus-dystonia affected by GI Microbiota?,” Am J Gastro, 106(S2):A940 (2011). cited by applicant
Borody et al., “Novel appearance of healing mucosa following anti-Mycobacterium avium paratuberculosis therapy for Crohn's disease,” J Gastroenterol Hepatol, 19(Suppl):A210 (2004). cited by applicant
Borody et al., Reversal of Idiopathic Thrombocytopenic Purpura [ITP] with Fecal Microbiota Transplantation [FMT], Am J Gastro, 106(S2):A941 (2011). cited by applicant
Borody et al., “Reversal of Inflammatory Bowel Disease (IBD) with Recurrent Faecal Microbiota Transplants (FMT),” Am J Gastro, 106(S2):A979 (2011). cited by applicant
Borody et al., “Severe recurrent Crohn's Disease of ileocolonic anastomosis and antimicrobial (anti-mycobacterial therapy),” Gut, 55:1211 (2006). cited by applicant
Borody et al., “The GI Microbiome and its Role in Chronic Fatigue Syndrome: a Summary of Bacteriotherapy,” ACNEM Journal, 31(3):3-8 (2012). cited by applicant
Borody et al., “Therapeutic faecal microbiota transplantation: current status and future developments,” Curr Opin Gastroenterol, 30:97-105 (2014). cited by applicant
Borody et al., “Treatment of chronic constipation and colitis using human probiotic infusions,” Proceedings of Prebiotics and Probiotics and the New Foods Conference, 2-4:228 Abstract (2001). cited by applicant
Borody et al., “Treatment of First-time Clostridium difficile Infection with Fecal Microbiota Transplantation,” Poster Presentation, 2015 ACG Annual Scientific Meeting, Honolulu, Hawaii, USA (2015). cited by applicant
Borody et al., “Treatment of Severe Constipation Improves Parkinson's Disease (PD) Symptoms,” Am J Gastro, 104(S3):A999 (2009). cited by applicant
Borody et al., “Treatment of Severe Crohn's Disease (CD)—Using Rifabutin-Macrolide-Clofazimine Combination: Results at 30-37 Months,” Gastroenterology, 118(4):A1334 Abstract (2000). cited by applicant
Borody et al., Treatment of Severe Crohn's Disease Using Rifabutin-Macrolide-Clofazimine Combination—Results at 38-43 Months, J Gastroenterol & Hepatol, 15(Suppl.):J102 (2000). cited by applicant
Borody et al., “Treatment of Severe Crohn's disease using antimycobacterial triple therapy—approaching a cure?,” Digest Liver Dis, 34(1):29-38 (2002). cited by applicant
Borody et al., “Treatment of ulcerative colitis using fecal bacteriotherapy,” J. Clin. Gastroenterol., 37(1):42-47 (2003). cited by applicant
Borody, “Bacteriotherapy for Chronic Fatigue Syndrome—A Long Term Follow-Up Study,” Proceedings of ACMA Complementary Medicine Sydney, p. 1 (1995). cited by applicant
Borody, “Flora Power—Fecal Bacteria Cure Chronic C. difficile Diarrhoea,” Am J Gastroenterol, 95(11):3028-3029 (2000). cited by applicant
Borody, “Is the Infected Patient too ‘Difficile’ to Treat?,” The Australian Society for Microbiology 2009 Perth, SY03 & SY03.1, p. 27 & 56, (2009). cited by applicant
Borody, “Letter to the Editor—Response to Drs. Famularo et al.,” AJG, 96(7):2262-2264 (2001). cited by applicant
Borriello, “Clostridial Disease of the Gut,” Clinical Infectious Diseases, The University of Chicago, 20(Suppl 2):S242-S250 (1995). cited by applicant
Bowden et al., “Pseudomembraneous enterocolitis: mechanism of restoring floral homeostasis,” Am Surg., 47(4):178-183 (1981). cited by applicant
Brandt et al., “Endoscopic Fecal Microbiota Transplantation: “First-Line” Treatment for Severe Clostridium difficile Infection?” J. Clin. Gastroenterol., 45(8):655-657 (2011). cited by applicant
Brandt et al., “Fecal microbiota transplantation for recurrent Clostridium difficile infection,” J Clin Gastroenterol., 45(Suppl):S159-S167 (2011). cited by applicant
Brandt et al., “Long-Term Follow-Up Study of Fecal Microbiota Transplantation (FMT) for Ulcerative Colitis (UC),” Am J. Gastroenterol., 107(Suppl 1):S657 (2012). cited by applicant
Brandt et al., Safety of Fecal Microbiota Transplantation (FMT) in Immunocompromised (Ic) Patients with Inflammatory Bowel Disease (IBD), Am J Gastroenterol, 108(Suppl 1):S556 (2013). cited by applicant
Browne et al., “Culturing of ‘unculturable’ human microbiota reveals novel taxa and extensive sporulation,” Nature, 533(7604):543-546 (2016). cited by applicant
Bueche et al., “Quantification of Endospore-Forming Firmicutes by Quantitative PCR with the Functional Gene spo0A,” Applied and Environmental Microbiology, 79(17):5302-5312 (2013). cited by applicant
Cammarota et al., “Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection,” Alimentary Pharmacology & Therapeutics, 41(9):835-843 (2015). cited by applicant
Cammorata et al., “Review article: biofile formation by Helicobacter pylori as a target for eradication of resistant infection,” Aliment Pharmacol Ther, 36:222-30 (2012). cited by applicant
Campbell et al., “The many faces of Crohn's Disease: Latest concepts in etiology,” OJIM, 2(2):107-115 (2012). cited by applicant
Cano et al., “Revival and identification of bacterial spores in 25-40 million year old Dominican Amber Science,” Science, 268(5213):1060-1064 (1995). cited by applicant
Cato et al., “Clostridium oroticum comb. nov. amended description,” International Journal of Systematic Bacteriology, 17(1):9-13 (1968). cited by applicant
Celik et al., “Factors influencing the stability of freeze-dried stress-resilient and stress-sensitive strains of bifidobacteria,” J. Dairy Sci., 96(6):3506-16 (2013). cited by applicant
Center for Disease Control, “Severe Clostridium difficile-associated disease in populations previously at low risk—four states, 2005.” Morbidity and Mortality Weekly Report, 54(47):1201-1205 (2005). cited by applicant
Chamberlain et al., “MAP-associated Crohn's Disease, MAP, Koch's postulates, causality and Crohn's Disease,” Digestive and Liver Disease, 39:790-794 (2007). cited by applicant
Chamberlin et al., “Primary treatment of Crohn's disease: combined antibiotics taking center stage,” Expert Rev. Clin. Immunol., 7(6):751-760 (2011). cited by applicant
Chang et al., “Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea,” J. Infect. Dis., 197(3):435-438 (2008). cited by applicant
Chen et al., “A mouse model of Clostridium difficile-associated disease,” Gastroenterology, 135(6):1984-1992 (2008). cited by applicant
Cherif et al., “Thuricin 7: a novel bacteriocin produced by Bacillus thuringiensis BMG1.7, a new strain isolated from soil,” Letters in Applied Microbiology, 32:243-7 (2001). cited by applicant
Chibani-Chennoufi et al., “In Vitro and In Vivo Bacteriolytic Activities of Escherichia coli Phages: Implications for Phage Therapy,” Antimicrobial Agents and Chemotherapy, 48(7):2558-2569 (2004). cited by applicant
Choi et al., “Fecal Microbiota Transplantation: Current Applications, Effectiveness, and Future Perspectives,” Clin. Endosc., 49:257-265 (2016). cited by applicant
Chopra et al., “Recent epidemiology of Clostridium difficile infection during hematopoietic stem cell transplantation,” Clin Transplant., 25(1):E82-E87 (2011). cited by applicant
Chu et al., “Profiling Living Bacteria Informs Preparation of Fecal Microbiota Transplantations,” PLoS One, 1-16 (2017). cited by applicant
Citron et al., “In Vitro Activities of CB-183,315, Vancomycin, and Metronidazole against 556 Strains of Clostridium difficile, 445 Other Intestinal Anaerobes, and 56 Enterobacteriaceae Species,” Antimicrob Agents Chemother., 56(3):1613-1615 (2012). cited by applicant
Claesson et al., “Comparison of two next-generation sequencing technologies for resolving highly complex microbiota composition using tandem variable 16S rRNA gene regions,” Nucleic Acids Research, 38(22):1-13 (2010). cited by applicant
Clancy et al., “Anti-MAP Therapy Induces and Maintains Remission in Severe Crohn's Disease,” Ann NY Acad Sci, p. 1 (2005). cited by applicant
Claus et al., “Colonization-induced host-gut microbial metabolic interaction,” MBio, 2(2):e00271-00210 (2011). cited by applicant
Claus et al., “Systemic multicompartmental effects of the gut microbiome on mouse metabolic phenotypes,” Mol. Syst. Biol., 4(1):219 (2008). cited by applicant
Cohen et al., “Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA),” Infect Control Hosp Epidemiol., 31(5):431-55 (2010). cited by applicant
Collins et al., “The Phylogeny of the Genus Clostridium: Proposal of Five New Genera and Eleven New Species Combinations,” International Journal of Systematic Bacteriology, pp. 812-826 (1994). cited by applicant
U.S. Appl. No. 12/843,409, filed Jul. 26, 2010. cited by applicant
Crohn's Disease, Prevention, Health Guide A-Z, WebMDHealth, pp. 1-2, n.d., Web, Oct. 23, 2005 . cited by applicant
Crowther, “Transport and Storage of Faeces for Bacteriological Examination,” Journal of Applied Bacteriology, 34(2):477-483 (1971). cited by applicant
Cutolo et al., “Fecal feedings as a therapy in Staphylococcus enterocolitis,” NY State J Med, 59:3831-3833 (1959). cited by applicant
Dale et al., “Molecular interactions between bacterial symbionts and their hosts,” Cell, 126(3):453-465 (2006). cited by applicant
Dan et al., “Comparison of preservation media and freezing conditions for storage of specimens of faeces,” J. Med Microbiology, 28:151-154 (1989). cited by applicant
De Giulio et al., “Use of Algiinate and Cryo-Protective Sugars to Improve the Viability of Lactic Acid Bacteria After Freezing and Freeze-Drying,” World Journal of Microbiology & Biotechnology, 21:739-746 (2005). cited by applicant
Defang et al., “In vitro and in vivo evaluation of two extended release preparations of combination metformin and glipizide,” Drug Develop. & Indust. Pharm., 31:677-685 (2005). cited by applicant
Definition of Kit, Merriam-Webster, pp. 1-10., Web., 2019 . cited by applicant
Dendukuri et al., “Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review,” CMAJ, 173(2):167-170 (2005). cited by applicant
Derwent Abstract Accession No. 98-230427/20, WO 98/13068 A, (Kuperman VB) Apr. 2, 1998. cited by applicant
Dethlefsen et al., “An ecological and evolutionary perspective on human-microbe mutualism and disease,” Nature, 449(7164):811-811 (2007). cited by applicant
Dewhirst et al., “Phylogeny of the Defind Murine Microbiota: Altered Schaedler Flora,” Applied and Environmental Microbiology, 65(8):3287-3292 (1999). cited by applicant
DuPont, “The search for effective treatment of Clostridium difficile infection,” N Engl J Med., 364(5):473-475 (2011). cited by applicant
Eckburg et al., “Diversity of the human intestinal microbial flora,” Science, 308(5728):1635-1638 (2005). cited by applicant
Eiseman et al., “Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis,” Surgery, 44(5):854-859 (1958). cited by applicant
Eller et al., “Anaerobic Roll Tube Media for Nonselective Enumeration and Isolation and Bacteria in Human Feces,” Applied Microbiology, 22(4):522-529 (1971). cited by applicant
Extended European Search Report dated Apr. 3, 2014, in European Patent Application No. 11813951.8. cited by applicant
Extended European Search Report dated Mar. 16, 2018, in European Patent Application No. 17203052.0. cited by applicant
Extended European Search Report dated Nov. 30, 2016, in European Patent Application No. 16193790.9. cited by applicant
Faust et al., “Treatment of recurrent pseudomembranous colitis (RPMC) with stool transplantation (ST): Report of six (6) cases,” Can J Gastroenterol., 16:A43 (2002). cited by applicant
Fenton et al., “Pseudomembranous colitis associated with antibiotic therapy—an emerging entity,” Can Med Assoc J., 111(10):1110-1111 (1974). cited by applicant
Floch et al., “Probiotics and Dietary Fiber, The Clinical Coming of Age of Intestinal Microecology,” J. Clin. Gastroenterology, 27(2):99-100 (1998). cited by applicant
Floch, “Fecal Bacteriotherapy, Fecal Transplant, and the Microbiome,” J. Clin. Gastroenterol., 44(8):529-530 (2010). cited by applicant
Flotterod et al., “Refractory Clostridium difficile infection. Untraditional treatment of antibiotic-induced colitis,” Tidsskr Nor Laegeforen, 111:1364-1365 (1991). cited by applicant
Frank et al., “Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases,” PNAS, 104(34):13780-13785 (2007). cited by applicant
Frantzen et al., “Empirical evaluation of preservation methods for faecal DNA,” Molecular Ecology, 7(10):1423-1428 (1998). cited by applicant
Freeman et al., “The changing epidemiology of Clostridium difficile infections,” Clin Microbiol. Rev., 23(3):529-549 (2010). cited by applicant
Frese et al., “The evolution of host specialization in the vertebrate gut symbiont Lactobacillus reuteri,” PloS Genet., 7(2):e1001314 (2011). cited by applicant
Gaboriau-Routhiau et al., “The Key Role of Segmented Filamentous Bacteria in the Coordinated Maturation of Gut Helper T Cell Responses,” Immunity, 31(4):677-689 (2009). cited by applicant
Garborg et al., “Results of faecal donor instillation therapy for recurrent Clostridium difficile-associated diarrhoea,” Scand J Infect Dis., 42(11-12):857-61 (2010). cited by applicant
Garey et al., “Meta-analysis to assess risk factors for recurrent Clostridium difficile infection,” J. Hosp. Infect., 70(4):298-304 (2008). cited by applicant
Gerding, “Management of Clostridium difficile infection: thinking inside and outside the box,” Clin Infect Dis., 57(11):1306-13 (2010). cited by applicant
Geuking et al., “Intestinal Bacterial Colonization Induces Mutualistic Regulatory T Cell Respones,” Immunity, 34:794-806 (2011). cited by applicant
Gitlin et al., “Mycobacterium avium ss paratuberculosis-associated Diseases: Piecing the Crohn's Puzzle Together,” J Clin Gastroenterol, 46(8):649-655 (2012). cited by applicant
Gough et al., “Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection,” Clin. Infect. Dis., 53(10):994-1002 (2011). cited by applicant
Grehan et al., “Durable alteration of the colonic microbiota by the administration of donor fecal flora,” Journal of Clinical Gastroenterology, 44(8):551-561 (2010). cited by applicant
Guamer et al., “Gut flora in health and disease,” Lancet, 361(9356):512-519 (2003). cited by applicant
Gustafsson et al., “The Effect of Faecal Enema on Five Microflora-Associated Characteristics in Patients with Antibiotic-Associated Diarrhoea,” Scandinavian Journal of Gastroenterology, 34:580-586 (1999). cited by applicant
Gustafsson et al., “Faecal Short-Chain Fatty Acids in Patients with Antibiotic-Associated Diarrhoea, before and after Faecal Enema Treatment,” Scand J Gastroenterol, 33:721-727 (1998). cited by applicant
Hamilton et al., “Change in microbial community composition of in patients with recalcitrant Clostridium difficile colitis treated with fecal bacteriotherapy,” International Human Microbiome Congress, Poster and Presentation, Vancouver, ON, Canada, Mar. 9-11, 2011. cited by applicant
Hamilton et al., “High-throughput DNA sequence analysis reveals stable engraftment of gut microbiota following transplantation of gut microbiota following transplantation of previously frozen fecal bacteria,” Gut Microbes, 4(2):1-11 (2013). cited by applicant
Hamilton et al., “Standardized Frozen Preparation for Transplantation of Fecal Microbiota for Recurrent Clostridium difficile Infection,” Article and Supplementary Material, Am. J. Gastroenterol., 107(5):761-767 (2012). cited by applicant
Hayashi et al., “Phylogenetic Analysis of the Human Gut Microbiota Using 16S rDNA Clone Libraries and Strictly Anaerobic Culture-Based Methods,” Microbiol. Immunol., 46(8):535-548 (2002). cited by applicant
Hecker et al., “Fecal Microbiota Transplantation by Freeze-Dried Oral Capsules for Recurrent Clostridium difficile Infection,” Open Forum Infect Dis, 3(2): 1-2 (2016). cited by applicant
Hellemans et al., “Fecal transplantation for recurrent Clostridium difficile colitis, an underused treatment modality,” Acta Gastroenterol Belg., 72(2):269-70 (2009). cited by applicant
Henriksson et al., “Probiotics under the regulatory microscope,” Expert Opin. Drug Saf., 4(6):1-9 (2005). cited by applicant
Hensel et al., “Vagal Ascent and Distribution of 125 I-Tetanus Toxin after Injection into the Anterior Wall of the Stomach,” Naunyn-Schmiedeberg's Arch. Pharmacol, 276:395-402 (1973). cited by applicant
Honda et al., “Regulation of T Cell Responses by Intestinal Commensal Bacteria,” Journal of Intestinal Microbiology, vol. 25, 2nd Edition:104 (2011). cited by applicant
Hongliang et al., “Freeze-dried, Capsulized Fecal Microbiota Transplantation for Relapsing Clostridium difficile Infection,” Journal of Clinical Gastroenterology, 43(6):537-538 (2015). cited by applicant
Hooper et al., “How host-microbial interactions shape the nutrient environment of the mammalian intestine,” Annu. Rev. Nutr., 22:283-307 (2002). cited by applicant
Hope et al., “Sporadic colorectal cancer-role of the commensal microbiota,” FEMS Microbiol. Lett., 244:1-7 (2005). cited by applicant
Hota et al., “Determining Mortality Rates Attributable to Clostridium difficile Infection,” Emerg. Infect. Dis., 18(2):305-301 (2012). cited by applicant
Hota et al., “Oral Vancomycin Followed by Fecal Transplant Versus Tapering Oral Vancomycin,” U.S. National Institutes of Health, Clinical Study No. NCT01226992, Oct. 20, 2010, last updated Jan. 14, 2013, Web, May 20, 2014, pp. 1-4 . cited by applicant
Hsu et al., “IL-10 Potentiates Differentiation of Human Induced Regulatory T Cells via STAT3 and Foxo1,” The Journal of Immunology, 3665-3674 (2015). cited by applicant
Hu et al., “Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection,” Gastroenterology, 136:1206-1214 (2009). cited by applicant
Huang et al., “Once-daily propranolol extended-release tablet dosage form: formulation design and in vitro/in vivo investigation,” European J. of Pharm. & Biopharm., 58:607-614 (2004). cited by applicant
Huttenhower et al., “Structure, function and diversity of the healthy human microbiome,” The Human Microbiome Project Consortium, Nature, 486:207-214 (2012). cited by applicant
Immunology in the 21st Century: Defeating Infection, Autoimmunity, Allergy, and Cancer, ICI 2010 Wrap-up Report, 14th International Congress of Immunology, pp. 1 (2010). cited by applicant
Inflammatory Bowel Disease Facts, Disease Prevention and Treatment Strategies, Crohn's Disease and Inflammatory Bowel Disease (IBD), HealingWithNutrition.com, pp. 1-4, n.d., Web, Oct. 23, 2005 . cited by applicant
Information Disclosure Statement filed Nov. 28, 2017, in U.S. Appl. No. 15/487,553. cited by applicant
International Preliminary Examination Report completed November 19, 2002, in International Application No. PCT/AU2001/000907, 19 pgs. cited by applicant
International Preliminary Report on Patentability completed Dec. 12, 2012, in International No. PCT/AU2011/000987, 35 pgs. cited by applicant
International Preliminary Report on Patentability completed Mar. 12, 2015, in International Application No. PCT/AU2013/001362, 29 pgs. cited by applicant
International Preliminary Report on Patentability dated Sep. 10, 2013, in International Application No. PCT/US2012/028484, 10 pgs. cited by applicant
International Search Report and Written Opinion (WO) dated Feb. 2, 2018 in International Application No. PCT/US2017/055618. cited by applicant
International Search Report and Written Opinion (WO) dated Feb. 2, 2018 in International Application No. PCT/US2017/056131. cited by applicant
International Search Report and Written Opinion (WO) dated Feb. 21, 2018 in International Application No. PCT/US2017/056129. cited by applicant
International Search Report and Written Opinion (WO) dated Jan. 17, 2018, in International Application No. PCT/US2017/045092. cited by applicant
International Search Report and Written Opinion (WO) dated Jan. 31, 2018 in International Application PCT/US2017/056126. cited by applicant
International Search Report and Written Opinion dated Aug. 17, 2018, in International Application No. PCT/US2018/034673. cited by applicant
International Search Report and Written Opinion dated Aug. 2, 2018, in International Application No. PCT/US2018/026074. cited by applicant
International Search Report and Written Opinion dated Jul. 30, 2018, in International Application No. PCT/US2018/026080. cited by applicant
International Search Report and Written Opinion dated Aug. 8, 2016, in International Application No. PCT/US2016/032695, 10 pgs. cited by applicant
International Search Report and Written Opinion dated Feb. 5, 2014, in International Application No. PCT/AU2013/001362, 17 pgs. cited by applicant
International Search Report and Written Opinion dated Jan. 5, 2017, in International Application No. PCT/US2016/058938. cited by applicant
International Search Report and Written Opinion dated Jul. 31, 2014, in International Application No. PCT/US2014/027391, 16 pgs. cited by applicant
International Search Report and Written Opinion dated Oct. 28, 2011, in International No. PCT/AU2011/000987, 18 pgs. cited by applicant
International Search Report dated Aug. 10, 2012, in International Application No. PCT/US2012/028484, 7 pgs. cited by applicant
International Search Report dated Jul. 29, 2014, in International Application No. PCT/AU2014/000478, 7 pgs. cited by applicant
International Search Report dated Sep. 22, 2017, in International Application No. PCT/US2017/040591, 12 pgs. cited by applicant
Irrgang et al., “The historical Development of Mutaflor therapy,” Ardeypharm GmbH, pp. 1-38 (1988) . cited by applicant
Irritable Bowel Syndrome (IBS), Health A to Z, InteliHealth, pp. 1-4, n.d., Web, Oct. 23, 2005 . cited by applicant
Issa et al., “Clostridium difficile and Inflammatory Bowel Disease,” Inflamm Bowel Dis., 14(10):1432-1442 (2008). cited by applicant
Issa et al., “Impact of Clostridium difficile on inflammatory bowel disease,” Clin. Gastroenterol. Hepatol., 5(3):345-351 (2007). cited by applicant
Itoh et al., “Characterization of clostridia isolated from faeces of limited flora mice and their effect on caecal size when associated with germ-free mice,” Laboratory Animals, 19:111-118 (1985). cited by applicant
Itoh et al., “Intestinal bacteria antagonistic to Clostridium difficile in mice,” Laboratory Animals, 21:20-25 (1987). cited by applicant
Ivanov et al., “Specific Microbiota Direct the Differentiation of IL-17-Producing T-Helper Cells in the Mucosa of the Small Intestine,” Cell Host & Microbe, 4:337-349 (2008). cited by applicant
Jacob et al., “Single Delivery of High-Diversity Fecal Microbiota Preparation by Colonoscopy Is Safe and Effective in Increasing Microbial Diversity in Active Ulcerative Colitis,” Inflamm Bowel Dis., 0(0): 1-9 (2017). cited by applicant
Janeway et al., “Adaptive Immunity to Infection,” Immunobiology, 6th Edition, Chapter 10, p. 414 (2005). cited by applicant
Janeway, Jr. et al., “Autoimmune responses are directed against self antigens,” Immunobiology: The Immune System in Health and Disease, 5th Edition, pp. 1-4 (2001). cited by applicant
Jarvis et al., “National point prevalence of Clostridium difficile in US health care facility inpatients, 2008,” Am. J. Infect. Control, 37:263-270 (2009). cited by applicant
Johnson et al., “Interruption of Recurrent Clostridium difficile-Associated Diarrhea Episodes by Serial Therapy with Vancomycin and Rifaximin,” Clin. Infect. Dis., 44(6):846-848 (2007). cited by applicant
Johnson et al., “Rifaximin Redux: Treatment of recurrent Clostridium difficile infections with Rifaximin immediately post-vancomycin treatment,” Anaerobe, 15(6):290-291 (2009). cited by applicant
Kageyama et al., “Emendation of genus Collinsella and proposal of Collinsella stercoris sp. nov. and Collinsella intestinalis sp. nov.,” International Journal of Systematic and Evolutionary Microbiology, 50:1767-1774 (2000). cited by applicant
Kageyama et al., “Phylogenetic and phenotypic evidence for the transfer of Eubacterium aerofaciens to the genus Collinsella as Collinsella aerofaciens gen. nov., comb. nov.,” International Journal of Systematic Bacteriology, 49:557-565 (1999). cited by applicant
Kakihana et al., “Fecal microbiota transplantation for patients with steriod-resistant acute graft-versus-host disease of the gut,” Blood, 128(16):2083-2088 (2016). cited by applicant
Kamboj et al., “Relapse versus reinfection: surveillance of Clostridium difficile infection,” Clin Infect Dis., 53(10):1003-1006 (2011). cited by applicant
Kang et al., “Microbiota Transfer Therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study,”Microbiome, 5:10, 16 pages (2017). cited by applicant
Karas et al., “A review of mortality due to Clostridium difficile infection,” J Infect., 61(1):1-8 (2010). cited by applicant
Kassam et al., “Fecal transplant via retention enema for refractory or recurrent Clostridium difficile infection,” Arch Intern Med., 172(2):191-193 (2012). cited by applicant
Kelly et al., “Commensal gut bacteria: mechanisms of immune modulation,” Trends in Immunology, 26(6):326-333 (2005). cited by applicant
Kelly et al., “Clostridium difficile—more difficult than ever,” N. Engl. J. Med., 359(18):1932-1940 (2008). cited by applicant
Kelly et al., “Clostridium difficile colitis,” N. Engl. J. Med., 330(4):257-62 (1994). cited by applicant
Kelly et al., “Fecal Microbiota Transplant for Treatment of Clostridium difficile Infection in Immunocompromised Patients,” Am J Gastroenterol, 109:1065-1071 (2014). cited by applicant
Kelly et al., “Fecal microbiota transplantation for relapsing Clostridium difficile infection in 26 patients: methodology and results,” J. Clin. Gastroenterol., 46(2):145-149 (2012). cited by applicant
Keynan et al., “The Role of Regulatory T Cells in Chronic and Acute Viral Infections,” Clinical Infectious Diseases, 46:1046-1052 (2008). cited by applicant
Khanna et al., “A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents Recurrent Clostridium difficile Infection,” The Journal of Infectious Diseases, 214:173-81 (2016). cited by applicant
Khanna et al., “The epidemiology of community-acquired Clostridium difficile infection: a population-based study,” Am J Gastroenterol., 107(1):89-95 (2012). cited by applicant
Khanna et al., “The growing incidence and severity of Clostridium difficile infection in inpatient and outpatient settings,” Expert Rev Gastroenterol Hepatol., 4(4):409-16 (2010). cited by applicant
Kharidia et al., “The Activity of a Small Lytic Peptide PTP-7 on Staphylococcus aureus Biofilms,” J. Microbiol., 49(4):663-668 (2011). cited by applicant
Khoruts et al., “Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea,” J. Clin. Gastroenterol., 44(5):354-360 (2010). cited by applicant
Khoruts et al., “Therapeutic transplantation of the distal gut microbiota,” Mucosal Immunol., 4(1):4-7 (2011). cited by applicant
Kim et al., “Effect of Rifampin on the Plasma Concentration and the Clinical Effect of Haloperidol Concomitantly Administered to Schizophrenic Patients,” Journal of Clinical Psychopharmacology, 16(3):247-252 (1996). cited by applicant
Kim et al., “In Vitro Culture Conditions for Maintaining a Complex Population of Human Gastrointestinal Tract Microbiota,” Journal of Biomedicine and Biotechnology, 2011(Article ID 838040):1-10 (2011) . cited by applicant
Klaenhammer, “Bacteriocins of lactic acid bacteria,” Biochimie, 70:337-49 (1988). cited by applicant
Kleiman et al., “Comparison of two coprological methods for the veterinary diagnosis of fasciolosis,” Arquivo Brasileiro de Medicina Veterinária e Zootćcnica, 55(2):181-185 (2005). cited by applicant
Kobashi et al., “Metabolism of Sennosides by Human Intestinal Bacteria,” Journal of Medicinal Plant Research, 40(3):225-236 (1980). cited by applicant
Koch, “What size should a bacterium be? A question of scale,” Annu. Rev. Microbiol., 50:317-48 (1996). cited by applicant
Krogius-Kurikka et al., “Sequence analysis of percent G+C fraction libraries of human faecal bacterial DNA reveals a high number of Antinobacteria,” BMC Microbiology, 9(68):1-13 (2009). cited by applicant
Kuijper et al. “Update of Clostridium difficile Infection due to PCR Ribotype 027 in Europe, 2008,” Euro. Surveill., 13(31):Article 5 (2008). cited by applicant
Kuksal et al., “Formulation and In Vitro, In Vivo Evaluation of Extended-release Matrix Tablet of Zidovudine: Influence of Combination of Hydrophilic and Hydrophobic Matrix Formers,” AAPS Pharm., 7(1):E1-E9 (2006). cited by applicant
Kunde et al., “Safety, Tolerability, and Clinical Response After Fecal Transplantation in Children and Young Adults With Ulcerative Colitis,” JPNG, 56(6):597-601 (2013). cited by applicant
Kyne et al., “Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhea,” Lancet, 357(9251):189-93 (2001). cited by applicant
Kyne et al., “Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A,” N Engl J Med., 342(6):390-397 (2000). cited by applicant
Kyne et al., “Factors associated with prolonged symptoms and severe disease due to Clostridium difficile,” Age and Ageing, 28(2):107-13 (1999). cited by applicant
Kysela et al., “Serial analysis of V6 ribosomal sequence tags (SARST-V6): a method for efficient, high-throughput analysis of microbial community composition,” Environmental Microbiology, 7(3):356-364 (2005). cited by applicant
Labbé et al., “Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain,” Antimicrob Agents Chemother., 52(9):3180-7 (2008). cited by applicant
Lamontagne et al., “Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain,” Ann. Surg., 245(2):267-272 (2007). cited by applicant
Larsen et al., “Gut Microbiota in Human Adults with Type 2 Diabetes Differs from Non-Diabetic Adults,” PLoS One, 5(2): e9085-e9095 (2010). cited by applicant
Lau et al., “Bacteraemia caused by Anaerotruncus colihominisand emended description of the species,” J Clin Pathol, 59:748-752 (2006). cited by applicant
Lawson et al., “Anaerotruncus colihominis gen. nov., sp. nov., from human faeces,” International Journal of Systematic and Evoluntionary Microbiology, 54:413-417 (2004). cited by applicant
Lawson et al., “Anaerotruncus,” Bergey's Manual of Systematics of Archae and Bacteria, pp. 1-4 (2009). cited by applicant
Lee et al., “Prioritizing candidate disease genes by network-based boosting of genome-wide association data,” Genome Research, 21(1):1109-1121 (2011). cited by applicant
Lee et al., “The outcome and long-term follow-up of 94 patients with recurrent and refractory Clostridium difficile infection using single to multiple fecal microbiota transplantation vie retention enema,” European Journal Clinical Microbiology Infect Dis., 33:1425-1428 (2014). cited by applicant
Lee, “A Prospective Randomized Multi-Centre Trial of Fresh vs. Frozen- and-Thawed Human Biotherapy (Fecal Transplant) for Recurrent Clostridium difficile Infection,” U.S. National Institutes of Health, Clinical Study No. NCT01398969, pp. 1-4, last updated Feb. 27, 2014, Web, May 20, 2014 . cited by applicant
Leis et al., “Fecal microbiota transplantation: A ‘How-To’ guide for nurses,” Collegian, 22:445-451 (2015). cited by applicant
Leslie et al., “Trehalose and Sucrose Protect Both Membranes and Proteins in Intact Bacteria during Drying,” Applied and Environmental Microbiology, 61:3592-3597 (1995). cited by applicant
Lewis et al., “Stool foim scale as a useful guide to intestinal transit time,” Scand. J. Gastroenterol., 32(9):920-924 (1997). cited by applicant
Ley et al., “Ecological and evolutionary forces shaping microbial diversity in the human intestine,” Cell, 124:837-848 (2006). cited by applicant
Ley et al., “Evolution of mammals and their gut microbes,” Science, 320(5883):1647-1651 (2008). cited by applicant
Ley et al., “Microbial ecology: human gut microbes associated with obesity,” Nature, 444(7722):1022-3 (2006). cited by applicant
Ley et al., “Worlds within worlds: evolution of the vertebrate gut microbiota,” Nat. Rev. Microbiol., 6(10):776-788 (2008). cited by applicant
Lin et al., “Twelve Week Storage Trial of Microbial Viability in Lyophilized and Frozen Fecal Microbiota Preparations,” Poster Presentation—Digestive Disease Week 2015, Washington, D.C. USA. cited by applicant
Longstreth, “Irritable bowel syndrome: A multibillion-dollar problem,” Gastroenterology, 109(6):2029-2031 (1995). cited by applicant
Loo et al., “A predominantly clonal multiinstitutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality,” N Engl J Med, 353(23):2442-9 (2005). cited by applicant
Loo et al., “Host and pathogen factors for Clostridium difficile infection and colonization,” N Engl J Med, 365(18):1693-703 (2011). cited by applicant
Louie et al., “Fidaxomicin versus vancomycin for Clostridium difficile infection,” N. Engl. J. Med., 364(5):422-431 (2011). cited by applicant
Louie et al., “Home-based fecal flora infusion to arrest multiply-recurrent C. difficile infection,” ICAAC/IDSA Conference, Abstract #K-4201 (2008). cited by applicant
Louis et al., “Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine,” FEMS Microbiology Letters, 294:1-8 (2009). cited by applicant
Lu, “Taboo transplant: How new poo defeats superbugs,” Science News, 1:90-91 (2011). cited by applicant
Ludwig et al., “Taxonomic outline of the phylum Firmicutes,” Bergey's Manual of Systematic Bacteriology, 3:15-17 (2009). cited by applicant
Lund-Tonnesen et al., “Clostridium difficile-associated diarrhea treated with homologous faeces,” Tidsskr Nor Lageforen, 118:1027-1030 (1998). cited by applicant
MacConnachie et al., “Faecal transplant for recurrent Clostridium difficile-associated diarrhoea: a UK case series,” QJM, 102(11):781-784 (2009). cited by applicant
MacDonald et al., “Formation of Ursodeoxycholic Acid from Chenodeoxycholic Acid by a 7β-Hydroxysteroid Dehydrogenase-Elaborating Eubacterium aerofaciens Strain Cocultured with 7α-Hydroxysteroid Dehydrogenase-Elaborating Organisms,” Applied and Environmental Microbiology, 44(5):1187-1195 (1982). cited by applicant
Macpherson et al., “Induction of Protective IgA by Intestinal Dendritic Cells Carrying Commensal Bacteria,” Science, 303:1662-1665 (2004). cited by applicant
Madsen, “The use of probiotics in gastrointestinal disease,” Can J Gastroenterol, 15(12):817-22 (2001). cited by applicant
Maizels et al., “Regulatory T cells in Infection,” Advances in Immunology, Chapter 3, 112:73-136 (2011). cited by applicant
Manichanh et al., “Reshaping the gut microbiome with bacterial transplantation and antibiotic intake,” Genome Research 20:1411-1419 (2010). cited by applicant
Marchesi et al., “The normal intestinal microbiota,” Curr. Opin. Infect. Dis., 20(5):508-513 (2007). cited by applicant
Martin, “Development and Delivery of a Treatment for Clostridium difficile,” Bacteriotherapy, pp. 1-2, n.d., Web, Feb. 10, 2012 . cited by applicant
Martin-Dejardin et al., “A way to follow the viability of encapsulated Bifidobacterium bifidum subjected to a freeze-drying process in order to target the colon: Interest of flow cytometry,” European Journal of Pharmaceutical Sciences, 49:166-74 (2013). cited by applicant
Maslowski et al., “Diet, gut microbiota and immune responses,” Nat Immunol., 12(1):5-9 (2011). cited by applicant
McDonald et al., “An Epidemic, Toxin Gene-Variant Strain of Clostridium difficile,” N Engl J Med., 353(23):2433-41 (2005). cited by applicant
McDonald et al., “Clostridium difficile Infection in Patients Discharged from US Short-stay Hospitals, 1996-2003” Emerg. Infect. Dis, 12(3):409-415 (2006). cited by applicant
McFarland et al., “Breaking the Cycle: Treatment Strategies for 163 Cases of Recurrent Herewith. Clostridium difficile Disease,” Am. J. Gastroenterol., 97(7):1769-1775 (2002). cited by applicant
McFarland et al., “Implications of the changing face of Clostridium difficile disease for health care practitioners,” Am J Infect Control., 35(4):237-253 (2007). cited by applicant
McFarland et al., “Meta-Analysis of Probiotics for the Prevention of Antibiotic Associated Diarrhea and the Treatment of Clostridium difficile Disease,” Am J Gastroenterol., 101(4):812-22 (2006). cited by applicant
McFarland et al., “Nosocomial Acquisition of Clostridium Difficile Infection,” N Engl J Med., 320(4):204-210 (1989). cited by applicant
McFarland et al., “Recurrent Clostridium Difficile Disease: Epidemiology and Clinical Characteristics,” Infect Control Hosp Epidemiol., 20(1):43-50 (1999). cited by applicant
McFarland et al., “Renewed interest in a difficult disease: Clostridium difficile infections—epidemiology and current treatment strategies,” Curr Opin Gastroenterol., 25(1):24-35 (2008). cited by applicant
Miller et al., “Health care-associated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality,” Clin Infect Dis., 50(2):194-201 (2010). cited by applicant
Miller et al., “Long-term follow-up of patients with fulminant Clostridium difficile colitis,” J. Gastrointest. Surg., 13(5):956-959 (2009). cited by applicant
Miller et al., “Morbidity, mortality, and healthcare burden of nosocomial Clostridium difficile-associated diarrhea in Canadian hospitals,” Infect Control Hosp Epidemiol., 23(3):137-40 (2002). cited by applicant
Miller, “The fascination with probiotics for Clostridium difficile infection: lack of evidence for prophylactic or therapeutic efficacy,” Anaerobe, 15(6):281-284 (2009). cited by applicant
Moayyedi et al., “Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial,” Gastroenterology, 149(1):102-9 (2015). cited by applicant
Molecular Studies in Autism, 2004 Funding Cycle, Cure Autism Now, Cure Autism Now Foundation, pp. 1-7 (2005) . cited by applicant
Momose et al., “16S rRNA gene sequence-based analysis of clostridia related to conversion of germfree mice to the normal state,” Journal of Applied Microbiology, 107:2088-2097 (2009). cited by applicant
Morris et al., “Clostridium difficile Colitis: An Increasingly Aggressive Iatrogenic Disease?” Arch Surg., 137(10):1096-1100 (2002). cited by applicant
Mucosal immunity: homeostasis (WS-064): Chairpersons: Toshiaki Ohteki, Makoto Iwata, International Immunology, 22:Suppl 1 Pt. 3, 1-9 (2010). cited by applicant
Mullard, “Microbiology: The Inside Story,” Nature, 453:578-580 (2008). cited by applicant
Murai et al., “Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis,” Nat Immunol., pp. 1-20 (2009). cited by applicant
Mutaflor, “Brief Summary of Therapeutic Principles,” Ardeypharm GmbH 0796 D-58313 Herdecke Germany, 6 pgs (2006). cited by applicant
Mutaflor, “For Functional and Inflammatory Bowel Diseases for Extraintestinal Manifestations for Activation of the Body's In-Built Defences,” Ardeypharm GmbH 0796, D-58313 Herdecke Germany, 8 pgs (2006). cited by applicant
Mutaflor, “Safety of Therapy,” Ardeypharm GmbH 0796, D-58313 Herdecke Germany, 4 pgs (1988). cited by applicant
Muto et al., “A Large Outbreak of Clostridium difficile-Associated Disease with an Unexpected Proportion of Deaths and Colectomies at a Teaching Hospital Following Increased Fluoroquinolone Use,” Infect Control Hosp Epidemiol., 26(3):273-80 (2005). cited by applicant
Nieuwdorp et al., [“Treatment of recurrent Clostridium difficile-associated diarrhoea with a suspension of donor faeces”], Ned Tijdschr Geneeskd, 152(35):1927-32 (2008) (English absract). cited by applicant
Niu et al., “Prevalence and Impact of Bacteriophages on the Presence of Escherichia coli O157:H7 in Feedlot Cattle and Their Environment,” Applied and Environmental Microbiology, 75(5): 1271-8 (2009). cited by applicant
O'Hara et al., “The gut flora as a forgotten organ,” EMBO Rep., 7(7):688-693 (2006). cited by applicant
O'Brien et al., “The emerging infectious challenge of clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences,” Infect Control Hosp Epidemiol., 28(11):1219-27 (2007). cited by applicant
O'Connor et al., “Clostridium difficile Infection Caused by the Epidemic BI/NAP1/027 Strain,” Gastroenterology, 136(6):1913-1924 (2009). cited by applicant
Office Action dated Sep. 18, 2015, in European Patent Application No. 11 728 077.6. cited by applicant
O'Garra et al., “IL-10—producing and naturally occuring CD4+ Tregs. limiting collateral damage,” The Journal of Clinical Investigation, 114:1372-1378 (2004). cited by applicant
O'Hara et al., “Functional modulation of human intestinal epithelial cell responses by Bifidobacterium infantis and Lactobacillus salivarius,” Immunology 118:202-215 (2006). cited by applicant
Okada et al., “Effects of Fecal Microorganisms and Their Chloroform-Resistant Variants Derived from Mice, Rats, and Humans on Immunological and Physiological Characteristics of the Intestines of Ex-germfree Mice,” Infection and Immunity, 62(12):5442-5446 (1994). cited by applicant
Olson et al., “The Gut Microbiota Mediates the Anti-Seizure Effects of the Ketogenic Diet,” Cell, 173:1728-1741 (2018) . cited by applicant
Ott et al., “Efficacy of Sterile Fecal Filtrate Transfer for Treating Patients With Clostridium difficile Infection,” Gastroenterology, 152(4):799-811 (2017). cited by applicant
Paramsothy et al., “Gastroenterologist perceptions of faecal microbiota transplantation,” World J Gastroenterol, 21(38): 10907-10914 (2015). cited by applicant
Paramsothy et al., “Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial,” The Lancet, published online, 11 pages (2017). cited by applicant
Paterson et al., “Putting back the bugs: Bacterial treatment relieves chronic diarrhoea,” Med J Aus, 160:232-233 (1994). cited by applicant
Patterson et al., “Special organism isolation: attempting to bridge the gap,” Infect Control Hosp Epidemiol., 15(5):335-338 (1994). cited by applicant
Pearce et al., “Modification of the colonic microflora using probiotics: The way forward?,” Gut, 41(Suppl 3):A63 (1997). cited by applicant
Pearce et al., “The use of probiotic therapy as a novel approach to the management of irritable bowel syndrome: a preliminary study,” J Gastroenterol & Hepatol, 12(Suppl):A129 (1997). cited by applicant
Pépin et al., “Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity,” CMAJ, 171(5):466-472 (2004). cited by applicant
Pépin et al., “Emergence of Fluoroquinolones as the Predominant Risk Factor for Clostridium difficile-Associated Diarrhea: A Cohort Study During an Epidemic in Quebec,” Clin Infect Dis., 41(9):1254-1260 (2005). cited by applicant
Pépin et al., “Management and Outcomes of a First Recurrence of Clostridium difficile-Associated Disease in Quebec, Canada,” Clin. Infect. Dis., 42:758-764 (2006). cited by applicant
Persky et al., “Treatment of recurrent Clostridium difficile-associated diarrhea by administration of donated stool directly through a colonoscope,” Am J Gastroenterol., 95(11):3283-3285 (2000). cited by applicant
Petrof et al.,“Stool substitute transplant therapy for the eradication of Clostridium difficile infection: ‘RePOOPulating’ the gut,” Microbiome, 1:3 (2013). cited by applicant
Petrof, “Harnessing the healthy gut microbiota to cure patients with recurrent C. difficile infection,” U.S. National Institutes of Health, Clinical Study No. NCT01372943, pp. 1-2, last updated Nov. 6, 2013, Web, May 22, 2014 . cited by applicant
Pillai et al., “Probiotics for treatment of Clostridium difficile-associated colitis in adults (Review),” Cochrane Database Syst Rev., (1):CD004611 (2008). cited by applicant
Porter, “Coating of pharmaceutical dosage forms,” In D.B. Troy (Ed.), Remington: The Science and Practice of Pharmacy, Chapter 46, pp. 929-938 (2005). cited by applicant
Poster 064-03 presented at the 14th International Congress of Immunology, Aug. 22-27, 2010, in Kyoto (Atarashi et al., Regulation of colonic regulatory T cells by Clostridium species). cited by applicant
Prakash et al., “Colon-targeted delivery of live bacterial cell biotherapeutics including microencapsulated live bacterial cells,” Biologics: Targets & Therapy, 2(3):355-378 (2008). cited by applicant
Prevention of Sudden Infant Death Syndrome, Healthtouch.com, Thomson Micromedex, pp. 1-4, n.d., Web, Nov. 23, 2005. cited by applicant
Qiu et al., “Faecalibacterium prausnitzii upregulates regulatory T cells and anti-inflammatory cytokines in treating TNBS-induced colitis,” Journal of Crohn's and Colitis, 7:e558-e568 (2013). cited by applicant
Rabeneck et al., “Bleeding and perforation after outpatient colonoscopy and their risk factors in usual clinical practice,” Gastroenterology, 135(6):1899-1906 (2008). cited by applicant
Rager et al., “Evaluation of rumen transfaunation after surgical correction of left-sided displacement of the abomasum in cows,” J. Am. Vet. Med. Assoc., 225(6):915-920 (2004). cited by applicant
Ramesh et al., “Prevention of Clostridium difficile-induced ileocecitis with Bacteriophage,” Anaerobe, 5:69-78 (1999). cited by applicant
Rao et al., “Evaluation of gastrointestinal transit in clinical practice: position paper of the American and European Neurogastroenterology and Motility Societies,” Neurogastroenterol. Motil., 23(1):8-23 (2011). cited by applicant
Rautava, “Potential uses of probiotics in the neonate,” Seminars in Fetal & Neonatal Medicine, 12:45-53 (2007). cited by applicant
Rea et al., “Gut solutions to a gut problem: bacteriocins, probiotics and bacteriophage for control of Clostridium difficile infection,” Journal of Medical Microbiology, 62:1369-1378 (2013). cited by applicant
Redelings et al., “Increase in Clostridium difficile-related mortality rates, United States, 1999-2004,” Emerg Infect Dis., 13(9):1417-1419 (2007). cited by applicant
Response to Office Action filed Feb. 25, 2014, in European Patent Application No. 11 728 077.6. cited by applicant
Response to Office Action filed Jan. 28, 2015, in European Patent Application No. 11 728 077.6. cited by applicant
Response to Office Action filed Nov. 18, 2015, in European Patent Application No. 11 728 077.6. cited by applicant
Rex et al., “American College of Gastroenterology guidelines for colorectal cancer screening 2008,” Am. J. Gastroenterol., 104(3):739-750 (2009). cited by applicant
Ricciardi et al., “Increasing prevalence and severity of Clostridium difficile colitis in hospitalized patients in the United States,” Arch Surg., 142(7):624-631 (2007). cited by applicant
Roberts, Generation and Development Microbial Drug Products, CSO Vedanta Biosciences, 1st Microbiome Drug Development Summit, pp. 1-17 (2016). cited by applicant
Rodemann et al., “Incidence of Clostridium difficile infection in inflammatory bowel disease,” Clin Gastroenterol Hepatol., 5(3):339-344 (2007). cited by applicant
Rohlke et al., “Fecal flora reconstitution for recurrent Clostridium difficile infection: results and methodology,” J Clin Gastroenterol., 44(8):567-570 (2010). cited by applicant
Rolfe et al., “Bacterial interference between Clostridium difficile and normal fecal flora,” J Infect Dis., 143(3):470-475 (1981). cited by applicant
Rossen et al., “Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients with Ulcerative Colitis,” Gastroenterology, 149(1):110-8 (2015). cited by applicant
Round et al., “Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota,” PNAS, 107(27):12204-12209 (2010). cited by applicant
Round et al., “The gut microbiota shapes intestinal immune responses during health and disease,” Nat. Rev. Immunol., 9(5):313-323 (2009). cited by applicant
Rupnik et al., “Clostridium difficile infection: new developments in epidemiology and pathogenesis,” Nat. Rev. Microbiol., 7(7):526-536 (2009). cited by applicant
Russell et al., “Fecal bacteriotherapy for relapsing Clostridium difficile infection in a child: a proposed treatment protocol,” Pediatrics, 126(1):e239-42 (2010). cited by applicant
Sambol et al., “Colonization for the prevention of Clostridium difficile disease in hamsters,” J. Infect. Dis., 186(12):1781-1789 (2002). cited by applicant
Sanchez et al., “The Role of Natural Regulatory T cells in Infection,” Immunol Res., 49(0):124-134 (2011). cited by applicant
Sandler et al., “Possible Gut-Brain Interaction Contributing to Delayed Onset Autism Symptomatology,” Fourth Int. Symp. Brain-Gut Interactions, Blackwell Science Ltd., 10(4):33 (1998). cited by applicant
Sandler et al., “Short-Term Benefit From Oral Vancomycin Treatment of Regressive-Onset Autism,” Journal of Child Neurology, 15(7):429-435 (2000). cited by applicant
Sartor, “Therapeutic correction of bacterial dysbiosis discovered by molecular techniques,” PNAS, 105(43):16413-16414 (2008). cited by applicant
Schiller, “Review article, the therapy of constipation,” Ailment Pharmacol. Ther., 15:749-763 (2001). cited by applicant
Schloss, “Introducing mothur: Open-Source, Platform-Independent, Community-Supported Software for Describing and Comparing Microbial Communities,” Appl. Environ. Microbiol., 75(23):7537-7541 (2009). cited by applicant
Schwan et al., “Relapsing Clostridium difficile Enterocolitis Cured by Rectal Infusion of Homologous Faeces,” The Lancet, 322(8354):845 (1983). cited by applicant
Schwan et al., “Relapsing Clostridium difficile Enterocolitis Cured by Rectal Infusion of Normal Faeces,” Scand. J. Infect. Dis., 16(2):211-215 (1984). cited by applicant
Seeff et al., “How many endoscopies are performed for colorectal cancer screening? Results from CDC's survey of endoscopic capacity,” Gastroenterology, 127:1670-1677 (2004). cited by applicant
Sekirov et al., “Gut microbiota in health and disease,” Physiol. Rev., 90(3):859-904 (2010). cited by applicant
Sell et al., “Bacteriophage and Bacteriocin Typing Scheme for Clostridium difficile,” Journal of Clinical Microbiology, 17(6):1148-1152 (1983). cited by applicant
Setlow, “I Will Survive: Protecting and Repairing Spore DNA,” Journal of Bacteriology, 174(9):2737-2741 (1992). cited by applicant
Setlow, “The bacterial spore: nature's survival package,” Culture, 26(2):1-4 (2005). cited by applicant
Sghir et al., “Quantification of Bacterial Groups within Human Fecal Flora by Oligonucleotide Prode Hybridization,” Applied and Environmental Microbiology, 66(5):2263-2266 (2000). cited by applicant
Shi et al., “Fecal Microbiota Transplantation for Ulcerative Colitis: A Systematic Review and Meta-Analysis,” PLoS One, 1-18 (2016). cited by applicant
Shim et al., “Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhea,” The Lancet, 351(9103):633-666 (1998). cited by applicant
Silverman et al., “Success of self-administered home fecal transplantation for chronic Clostridium difficile infection,” Clin. Gastroenterol. Hepatol., 8(5):471-473 (2010). cited by applicant
Simor et al., “Clostridium difficile in long-term-care facilities for the elderly,” Infect Control Hosp Epidemiol., 23(11):696-703 (2002). cited by applicant
Singh et al., “Do NSAIDs, antibiotics, infections, or stress trigger flares in IBD?” Am J Gastroenterol., 104(5):1298-1313 (2009). cited by applicant
Sleator, “The human superorganism—of microbes and men,” Med. Hypotheses, 74(2):214-215 (2010). cited by applicant
Smits et al., “Therapeutic potential of fecal microbiota transplantation,” Gastroenterology, 145:946-953 (2013). cited by applicant
Sokol et al., Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients, Proceedings of the National Academy of Sciences, 105(43):16731-16736 (2008). cited by applicant
Sokol et al., “Low Counts of Faecalibacterium prausnitzii in Colitis Microbiota,” Inflamm. Bowel Dis., pp. 1-7 (2009). cited by applicant
Sullivan et al., “Effect of supplement with lactic-acid producing bacteria on fatigue and physical activity in patients with chronic fatigue syndrome,” Nutritional Journal, 8(4):1-6 (2009). cited by applicant
Sunil et al., “Design and evaluation of lornoxicam bilayered tablets for biphasic release,” Brazilian Journal of Pharmaceutical Sciences, 48(4):609-19 (2012). cited by applicant
Surawicz et al., “Treatment of refractory and recurrent Clostridium difficile infection,” Nat. Rev. Gastroenterol. Hepatol., 8(6):330-339 (2011). cited by applicant
Surawicz, “Reining in Recurrent Clostridium difficile Infection—Who's at Risk?,” Gastroenterology, 136:1152-1154 (2009). cited by applicant
Sutherland et al., “Lyophilized Clostridium perfringens 3 alpha- and Clostridium bifermentans 7 alpha-hydroxysteroid dehydrogenases: two new stable enzyme preparations for routine bile acid analysis,” Biochim Biophys Acta, 962(1):116-121 (1988). cited by applicant
Takaishi et al., “Imbalance in intestinal microflora constitution could be involved in the pathogenesis of inflammatory bowel disease,” J. Med. Microbiol., 298:463-472 (2008). cited by applicant
Takeda et al., “Serum Haloperidol Levels of Schizophrenics Receiving Treatment for Tuberculosis,” Clinical Neuropharmacology, 9(4):386-397 (1986). cited by applicant
Tannock et al., “A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin,” Microbiology, 156(11):3354-3359 (2010). cited by applicant
Tanoue et al., “Immune response to gut microbiota-commensals and pathogens,” Gut Microbes, 1(4):224-233 (2010). cited by applicant
Taras et al., “Reclassification of Eubacterium formicigenerans Holdeman and Moore 1974 as Dorea formicigenerans gen. nov., comb. nov., and description of Dorea longicatena sp. nov., isolated from human faeces,” International Journal of Systematic and Evolutionary Microbiology, 52:423-428 (2002). cited by applicant
Teasley et al., “Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis,” The Lancet, 2(8358):1043-1046 (1983). cited by applicant
Tian et al., Journal of Clinical Gastroenterology, 49(6):537-538 (2015). cited by applicant
Tilg et al., “Gut microbiome, obesity, and metabolic dysfunction,” J. Clin. Invest., 121(6):2126-2132 (2011). cited by applicant
Tvede et al., “Bacteriotherapy for chronic relapsing Clostridium difficile diarrhea in six patients,” The Lancet, 1:1156-1160 (1989). cited by applicant
Van Andel et al., “Interleukin-12 Has a Role in Mediating Resistance of Murine Strains to Tyzzer's Disease,” Infect. Immun., 66(10):4942-4946 (1998). cited by applicant
Van der Waaij et al., “Direct Flow Cytometry of Anaerobic Bacteria in Human Feces,” Cytometry, 16:270-279 (1994). cited by applicant
Van Immerseel et al., “Butyric acid-producing anaerobic bacteria as a novel probiotic treatment approach for inflammatory bowel disease,” Journal of Medical Microbiology, 59:141-143 (2010). cited by applicant
Van Nood et al., “Struggling with Recurrent Clostridium difficile Infections: Is Donor Faeces the Solution?,” Euro Surveill., 14(34):1-6 (2009). cited by applicant
Van Nood, “Duodenal infusion of donor feces for recurrent Clostridium difficile,” New England Journal of Medicine, 368(5):407-415 (2013). cited by applicant
Vaughn et al., “Novel treatment options for ulcerative colitis,” Future Science, 1-20 (2013). cited by applicant
Veldhuyzen van Zanten et al., “Drug Treatment of Functional Dyspepsia: A Systematic Analysis of Trial Methodology with Recommendations for Design of Future Trials,” Am. J. Gastroenterol., 91(4):660-673 (1996). cited by applicant
Veldhuyzen van Zanten et al., “Validation of a 7-point Global Overall Symptom scale to measure the severity of dyspepsia symptoms in clinical trials,” Ailment Pharmacol. Ther., 23(4):521-529 (2006). cited by applicant
Venugopal et al., “Fidaxomicin: A Novel Macrocyclic Antibiotic Approved for Treatment of Clostridium difficile Infection,” Clin Infect Dis, 54(4):568-74 (2012). cited by applicant
Vrieze et al., “The environment within: how gut microbiota may influence metabolism and body composition,” Diabetologia, 53(4):606-613 (2010). cited by applicant
Vulevic et al., “Modulation of the fecal microflora profile and immune function by a novel trans-galactooligosaccharide mixture (B-GOS) in healthy elderly volunteers,” Am J Clin Nutr, 88:1438-46 (2008). cited by applicant
Wachsmann et al., “Characterization of an Orotic Acid Fermenting Bacterium, Zymobacterium oroticum, nov. gen., nov. spec.,” Journal of Bacteriology, 68(4):400-404 (1954). cited by applicant
Walter et al., “Host-microbial symbiosis in the vertebrate gastrointestinal tract and the Lactobacillus reuteri paradigm,” PNAS USA, 108(Suppl 1):4645-4652 (2011). cited by applicant
Warny et al., “Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe,” Lancet, 366(9491):1079-84 (2005). cited by applicant
Warren et al., “Clostridium aldenense sp. nov. and Clostridium citroniae sp. nov. Isolated from Human Clinical Infections,” Journal of Clinical Microbiology, 44(7):2416-2422 (2006). cited by applicant
Wasfy et al., “Comparison of Preservation Media for Storage of Stool Samples,” Journal of Clinical Microbiology, 33(8):2176-2178 (1995). cited by applicant
Weingarden et al., “Dynamic changes in short- and long-term bacterial composition following fecal microbiota transplantation for recurrent Clostridium difficile infection,” Microbiome, 3(10), 8 pages (2015). cited by applicant
Weissman et al., “Stool Transplants: Ready for Prime Time?,” Current Gastroenterology Reports, 14:313-316 (2012). cited by applicant
Wells et al., “Clostridia: Sporeforming Anaerobic Bacilli,” Medical Microbiology—NCBI Bookshelf, 4th Edition, Chapter 18, pp. 1-20 (1996) . cited by applicant
Wenisch et al., “Comparison of Vancomycin, Teicoplanin, Metronidazole, and Fusidic Acid for the Treatment of Clostridium difficile-Associated Diarrhea,” Clin Infect Dis., 22(5):813-818 (1996). cited by applicant
Wettstein et al., “Fecal Bacteriotherapy—An effective Treatment for Relapsing Symptomatic Clostridium difficile Infection,” Abstract, 15th United European Gastroenterology Week (UEGW) Poster presentations, United European Gastroenterology Federation, France, A303 (2007). cited by applicant
Wettstein et al., “Skewered diverticulum: another cause of abdominal pain,” Internal Med J, 31(8):495-496 (2001). cited by applicant
Wikoff et al., “Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites,” PNAS, 106(10):3698-3703 (2009). cited by applicant
Wilson et al., “Human Colonic Biota Studied by Ribosomal DNA Sequence Analysis,” Appl. Environ. Microbiol., 62(7):2273-2278 (1996). cited by applicant
Yoon et al., “Treatment of Refractory/Recurrent C. difficile-associated Disease by Donated Stool Transplanted Via Colonoscopy: A Case Series of 12 patients,” J Clin Gastroenterol., 44(8):562-566 (2010). cited by applicant
You et al., “Successful treatment of fulminant Clostridium difficile infection with fecal bacteriotherapy,” Ann. Intern. Med., 148(8):632-633 (2008). cited by applicant
Youngster et al., “Oral, Capsulized, Frozen Microbiota Transplantation for Relapsing Clostridium difficile Infection,” American Medical Association, 312 (174) 1772-1778 (2014). cited by applicant
Yue et al., “Similarity Measure Based on Species Proportions,” Commun. Stat. Theor. Methods, 34(11):2123-2131 (2005). cited by applicant
Zar et al., “A Comparison of Vancomycin and Metronidazole for the Treatment of Clostridium difficile-Associated Diarrhea, Stratified by Disease Severity,” Clin Infect Dis., 45(3):302-307 (2007). cited by applicant
Zhang et al, “Influence of Microbiota on Intestinal Immune System in Ulcerative Colitis and Its Intervention,” Frontiers in Immunology, 8(Article 1674):1-11 (2017). cited by applicant
Zhang et al., “Altered gut microbiome composition in children with refractory epilepsy after ketogenic diet,” Epilepsy Research (2018) . cited by applicant
Zhou et al., “Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota,” Scientific Reports (Nature), 7(1529):1-11 (2017). cited by applicant
Zilberberg et al., “Clostridium difficile Infections amoung Hospitalized Children,” Emerg. Infect. Dis, 16(4):604-609 (2010). cited by applicant
Zilberberg et al., “Clostridium difficile-related Hospitalizations amoung US Adults,” Emerg. Infect. Dis, 15(1):122-124 (2009). cited by applicant
Zilberberg et al., “Increase in Adult Clostridium difficile-related Hospitalization and Case-Fatality Rate,” Emerg. Infect. Dis, 14(6):929-931 (2008). cited by applicant
Zilberberg et al., “Increase in Clostridium difficile-related Hospitalizations Amoung Infants in the United States, 2001-2005” Pediatr Infect Dis. J, 27(12):1111-1113 (2008). cited by applicant
Zoppi et al., “Oral Bacteriotherapy in Clinical Practice,” Eur J. Pediatr, 139(1):18-21 (1982). cited by applicant
Zoppi et al., “The Intenstinal Ecosystem in Chronic Functional Constipation,” ACTA Paediatr, 836-841 (1998). cited by applicant

edspgr.11213549